“In clinical trials, TIVDAK demonstrated a superior overall survival benefit and manageable safety profile compared to chemotherapy, supporting its position to become a potential new standard of ...

Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical cancer, confirming its ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer ...

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global Phase 3 ...

(RTTNews) - Genmab A/S (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK for the treatment of advanced or recurrent cervical cancer that has progressed on ...

Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK ® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...